Multiple ongoing clinical trials are evaluating disitamab vedotin in HER2-positive solid tumors, including urothelial bladder cacinomas (NCT05495724), advanced or metastatic colorectal cancer (NCT05493683, NCT05333809), and locally advanced or metastatic NSCLC (NCT05847764). This evidence concerns the gene ERBB2 and metastatic colorectal cancer.